USPTO Examiner WRIGHT SARAH C - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18435068SOLANUM LYCOPERSICUM SEED OIL FREEZE-DRIED POWDER WITH WHITENING EFFICACY, COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOFFebruary 2024June 2025Allow1621NoNo
18432437POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATIONFebruary 2024May 2025Abandon1510NoNo
184144459-(5-BROMO-2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024March 2024Allow200NoNo
184144429-(5-BROMO-2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024May 2024Allow401NoNo
183828879-(5-BROMO-2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow511NoNo
18465918COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIASeptember 2023August 2024Abandon1111NoNo
18332194TRANSDERMAL ADHESIVE COMPOSITION COMPRISING A POORLY SOLUBLE THERAPEUTIC AGENTJune 2023September 2024Abandon1610NoNo
18332434Composition Containing a Cellulose Derived Capsule With a SunscreenJune 2023May 2025Abandon2320NoNo
18103998UNIVERSAL MINERAL BASED SUNSCREEN AND RELATED METHODS OF MANUFACTUREJanuary 2023July 2024Allow1821NoNo
18076951Method And Device for Treating Venous Insufficiency And Varicose VeinsDecember 2022June 2024Allow1911NoNo
17925849A HIGH UV PROTECTION CLEANSING COMPOSITIONNovember 2022November 2024Abandon2431NoNo
18054185SOLID DOSAGE FORMS OF TAFAMIDISNovember 2022August 2023Abandon901NoNo
18053193ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDSNovember 2022January 2025Abandon2701NoNo
18053322Compositions Containing a Capsule with an AgentNovember 2022May 2024Abandon1911NoNo
17995174Method for manufacturing spicule coated with diamond and ingredients effective for skin improvement, and diamond spicule cosmetic composition including the sameSeptember 2022May 2025Allow3111NoNo
17932469Topical Delivery System Containing Cellulose NanofibersSeptember 2022August 2024Abandon2320YesNo
17863754DOSAGE FORMS OF TAFAMIDIS AND ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOFJuly 2022October 2023Abandon1511NoNo
17844904LIGHT AESTHETIC SUNSCREEN COMPOSITIONSJune 2022August 2024Abandon2620NoNo
17843440COSMETIC COMPOSITION HAVING INCREASED SKIN CONTACT AND MAKEUP PERSISTENCE AND METHOD OF MANUFACTURING SAMEJune 2022October 2023Allow1620NoNo
17743501TRIAZINE FORMULATIONS WITH A SECOND ACTIVE INGREDIENT AND SURFACTANT(S)May 2022October 2023Allow1710NoNo
17733344METHOD OF MANAGING DIFFERENT STAGES IN A WOMEN'S LIFEApril 2022September 2023Abandon1621YesNo
17715369COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAApril 2022April 2025Abandon3601NoNo
17633350EXTRACT OF MORINGA PEREGRINA SEED CAKE, METHOD FOR OBTAINING SAME AND USE THEREOF IN COSMETIC OR NUTRICOSMETIC COMPOSITIONSFebruary 2022February 2025Allow3631NoNo
17627439METHOD FOR MICRO-ENCAPSULATION OF NATURAL INGREDIENTS BY MEANS OF CONTACTING WITH SUPERCRITICAL GASJanuary 2022April 2025Abandon3910NoNo
17624149PRESSED POWDER COMPOSITIONDecember 2021May 2024Abandon2821YesNo
17545206SKIN CARE COMPOSITIONS AND METHODS FOR REGULATING SEBUM PRODUCTIONDecember 2021September 2022Allow921YesNo
17539101SKIN BRIGHTENING COMPOSITIONNovember 2021November 2023Abandon2310NoNo
17530003DOSAGE FORMS OF TAFAMIDIS AND ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOFNovember 2021September 2022Allow1011YesNo
17453964MEDICAL MOISTURIZING EYE PATCH AND PREPARATION METHOD THEREOFNovember 2021January 2025Allow3810NoNo
17494870TRIAZINE FORMULATIONS WITH A SECOND ACTIVE INGREDIENT AND SURFACTANT(S)October 2021October 2023Allow2410YesNo
17494866TRIAZINE FORMULATIONS WITH A SECOND ACTIVE INGREDIENT AND SURFACTANT(S)October 2021October 2023Allow2410YesNo
17441533IMPLANTABLE OCULAR DRUG DELIVERY DEVICES AND METHODSSeptember 2021June 2025Abandon4501NoNo
17470971PETROLATUM-BASED DELIVERY SYSTEMS AND FOR ACTIVE INGREDIENTSSeptember 2021September 2024Abandon3711NoNo
17468809PETROLATUM-BASED COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSISSeptember 2021June 2025Allow4521NoNo
17467406PETROLATUM-BASED PHMB COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSISSeptember 2021May 2024Allow3211NoNo
17434390HYDROGEL COMPOSITIONS AND METHODS FOR TREATMENT OF MALIGNANCIESAugust 2021April 2025Abandon4301NoNo
17394332Compositions and Methods for Preparation of Solidified Oil for Treating Hair and ScalpAugust 2021May 2024Abandon3421YesNo
17427369NON-THERAPEUTIC ORAL USE OF A COMPOSITION FOR WHITENING AND/OR LIGHTENING THE SKIN COMPRISING CYSTINE AND GLUTATHIONE IN A CYSTINE-GLUTATHIONE RATIO RANGING FROM 1.5 TO 4July 2021February 2024Allow3141NoNo
17419524MICROPARTICLES OF CELLULOSE NANOCRYSTALS WITH PIGMENT NANOPARTICLES BOUND THERETO AND METHOD OF PRODUCTION THEREOFJune 2021May 2024Allow3531NoNo
17356136ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGSJune 2021May 2025Abandon4731NoNo
17344077Hair Or Skin Treatment Composition And Methods Of Preparation And UseJune 2021April 2024Allow3421NoNo
17327972PERSONAL CARE COMPOSITIONS SUBSTANTIALLY FREE OF SULFATED SURFACTANTS AND CONTAINING A GEL NETWORKMay 2021September 2024Allow4040NoNo
17326485SILVER ION BACTERIOSTATIC HAND SANITIZER AND PREPARATION METHOD AND APPLICATION THEREOFMay 2021September 2021Allow401YesNo
17291544COSMETIC COMPOSITIONMay 2021December 2022Abandon2030YesNo
17222061PETROLATUM-BASED DELIVERY SYSTEMS AND FOR ACTIVE INGREDIENTSApril 2021May 2024Allow3720NoNo
17278922INSECTICIDAL COMPOUNDSMarch 2021September 2024Abandon4101NoNo
17190754MANUFACTURING PROCESS FOR 2-PHASE SPRAY CONDITIONERMarch 2021November 2023Allow3211NoNo
17271147THERAPEUTIC COMBINATIONS OF CANNABINOIDS WITH CURCUMINFebruary 2021September 2024Abandon4201NoNo
17161446POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATIONJanuary 2021February 2024Abandon3611NoNo
17258357METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID-RELATED DISORDERSJanuary 2021May 2025Allow5211NoNo
17258262A COMPOSITION CONTAINING CASHEW LEAF EXTRACT AND PRODUCTION METHOD THEREOFJanuary 2021February 2024Abandon3701NoNo
17136353SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USEDecember 2020May 2025Abandon5341NoYes
17135646PETROLATUM-BASED COMPOSITIONS COMPRISING CATIONIC BIOCIDESDecember 2020May 2024Allow4111NoNo
17255574A METHOD OF PROVIDING CUSTOMIZED COLOR SHADE SUNSCREEN PRODUCTSDecember 2020April 2025Abandon5131YesNo
17127365Sunscreen and Bug Repellant FormulaDecember 2020August 2023Abandon3211NoNo
17123274CLEANSING CREAM FORMULATIONDecember 2020September 2022Allow2110NoNo
17116966Composition For Providing High Lift And Color DepositDecember 2020June 2023Abandon3131NoNo
17114769Temporary Hair ColoringDecember 2020December 2023Abandon3621NoNo
16972530COSMETIC COMPOSITION FOR SKIN WHITENINGDecember 2020July 2023Abandon3211NoNo
17108361WATER-IN-OIL EMULSION COMPOSITIONDecember 2020August 2022Abandon2010NoNo
17104350COSMETIC COMPOSITION HAVING INCREASED SKIN CONTACT AND MAKEUP PERSISTENCE AND METHOD OF MANUFACTURING SAMENovember 2020October 2022Abandon2310NoNo
17057320SKIN LIGHTENING AGENTNovember 2020September 2024Allow4621NoYes
17054265STATIN-ENCAPSULATED NANOPARTICLE PREPARATION, DENTAL PULP-DERIVED STEM CELLS CONTAINING SAME, AND CELL PREPARATION CONTAINING SUCH STEM CELLSNovember 2020October 2024Abandon4740NoYes
17086859MINERAL BASED COMPOSITIONS AND USE THEREOFNovember 2020July 2023Allow3311YesNo
17035682HERBAL COMPOSITION FOR GERMINATING HAIR, REJUVENATING HAIR VOLUME AND MANUFACTURING METHOD THEREOFSeptember 2020April 2023Abandon3121NoNo
17024911SKIN BRIGHTENING COMPOSITIONSeptember 2020September 2021Allow1111YesNo
17024761DECORATING POWDER COMPOSITIONSeptember 2020January 2023Allow2821YesNo
16757055FRAGRANCE COMPOSITION FOR MASKING OR DEODORIZING MAL-ODORSeptember 2020May 2025Abandon6031YesNo
16981788TOPICAL COMPOSITIONSeptember 2020November 2023Allow3821NoYes
17020567OIL-BASED WOUND CARE COMPOSITIONS AND METHODSSeptember 2020December 2024Allow5131NoNo
15733560ELONGATE SCAFFOLD COMPRISING INNER AND OUTER PORTIONAugust 2020April 2024Abandon4401NoNo
17003558HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USEAugust 2020May 2025Abandon5651NoYes
17002941PORE HIDING COSMETIC COMPOSITION COMPRISING A PLATE TYPE FILLER, A SILICON ELASTOMER AND AN OIL ABSORBING FILLERAugust 2020July 2023Allow3430NoYes
16971358CELL ADHESIVE MATERIALAugust 2020June 2024Allow4611NoNo
16996593COMPOSITION FOR REMOVING ALDEHYDE-BASED ODORS AND REACTIVE OXYGEN SPECIESAugust 2020January 2024Abandon4131NoNo
16985902CONDITIONER COMPOSITION COMPRISING A CHELANTAugust 2020February 2021Allow620NoNo
16931880HAIR CARE COMPOSITIONS FOR CALCIUM CHELATIONJuly 2020March 2022Allow2040NoNo
16926069SOLID COSMETIC DETERGENTS (TWO-COMPONENT COMPOSITION)July 2020August 2024Abandon4941NoNo
16917966ORGANIC AND MINERAL FILTER HYBRID SUNSCREENJuly 2020April 2025Abandon5850NoYes
16917846PETROLATUM-BASED DELIVERY SYSTEMS AND FOR ACTIVE INGREDIENTSJune 2020December 2020Allow510NoNo
16913379COSMETIC COMPOSITIONS COMPRISING BIODEGRADABLE POLYMERSJune 2020April 2024Abandon4641NoNo
16911013Anti-Aging FormulaJune 2020May 2023Abandon3511NoNo
16910449NON-IRRITATING, NON-BLURRING, PHOTOSTABLE OPHTHALMIC SUNSCREEN COMPOSITIONJune 2020February 2023Allow3220NoNo
16905988FRAGRANCE-ENHANCING COMPOSITIONSJune 2020November 2023Allow4131YesNo
16903439CYCLIC HYDRAZIDES AS FRAGRANCE PRECURSOR COMPOUNDSJune 2020January 2024Abandon4321NoNo
16899156COSMETIC SHEET AND METHOD FOR PRODUCING THE SAMEJune 2020September 2024Abandon5141YesNo
16899219NANOEMULSION SYSTEM FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL COMPOSITIONS AND OTHER ACTIVE AGENTSJune 2020March 2023Abandon3311NoNo
16888118CRYOGENIC NATURAL SKIN CARE COMPOSITIONS AND CORRESPONDING METHODSMay 2020August 2022Allow2711YesNo
16883488ANTIAGING MICROMOLECULAR METHODMay 2020March 2023Abandon3321NoNo
16881570COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAMay 2020October 2020Allow511NoNo
16879639HEMP-BASED COSMECEUTICAL COMPOSITIONS AND METHODS OF MAKING SAMEMay 2020September 2024Allow5231NoNo
16763579COSMETIC COMPOSITION FOR BLURRING SURFACE IMPERFECTIONS OF SKINMay 2020May 2024Abandon4841NoNo
16872178PETROLATUM-BASED COMPOSITIONS COMPRISING CATIONIC BIOCIDESMay 2020October 2020Allow511YesNo
16762046HAIR CARE COMPOSITIONMay 2020January 2023Allow3321YesNo
16862694Nanopore Delivery DeviceApril 2020February 2022Abandon2211NoNo
16862059DETERGENT COMPOSITIONSApril 2020September 2024Allow5251YesNo
16859208Multi-Chrome Cosmetic Hair CompositionApril 2020June 2022Allow2611NoNo
16854944TOPICAL DELIVERY SYSTEM CONTAINING CELLULOSE NANOFIBERSApril 2020November 2022Abandon3021NoNo
16846379NATURAL HAIR CONDITIONING COMPOSITIONApril 2020February 2022Abandon2220NoNo
16845748NON-IRRITATING, NON-BLURRING OPHTHALMIC SUNSCREENApril 2020April 2022Allow2421NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WRIGHT, SARAH C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
31
Examiner Affirmed
18
(58.1%)
Examiner Reversed
13
(41.9%)
Reversal Percentile
63.7%
Higher than average

What This Means

With a 41.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
100
Allowed After Appeal Filing
23
(23.0%)
Not Allowed After Appeal Filing
77
(77.0%)
Filing Benefit Percentile
27.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WRIGHT, SARAH C - Prosecution Strategy Guide

Executive Summary

Examiner WRIGHT, SARAH C works in Art Unit 1619 and has examined 554 patent applications in our dataset. With an allowance rate of 39.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner WRIGHT, SARAH C's allowance rate of 39.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WRIGHT, SARAH C receive 2.82 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WRIGHT, SARAH C is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +51.2% benefit to allowance rate for applications examined by WRIGHT, SARAH C. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.0% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 82.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 61.3% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 42.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 72.1% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 49% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.